Approaches and challenges in SARS-CoV-2 vaccine development

Please use this identifier to cite or link to this item: http://repositorio.ufla.br/jspui/handle/1/43154

metadata.artigo.dc.title:	Approaches and challenges in SARS-CoV-2 vaccine development
metadata.artigo.dc.creator:	Dagotto, Gabriel Yu, Jingyou Barouch, Dan H.
metadata.artigo.dc.subject:	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) COVID-19 - Vaccine
metadata.artigo.dc.publisher:	Cell Press
metadata.artigo.dc.date.issued:	Sep-2020
metadata.artigo.dc.identifier.citation:	DAGOTTO, G.; YU, J.; BAROUCH, D. H. Approaches and challenges in SARS-CoV-2 vaccine development. Cell Host & Microbe, [S.l.], v. 28, n. 3, p. 364-370, Sept. 2020.
metadata.artigo.dc.description.abstract:	The explosive spread of SARS-CoV-2 suggests that a vaccine will be required to end this global pandemic. Progress in SARS-CoV-2 vaccine development to date has been faster than for any other pathogen in history. Multiple SARS-CoV-2 vaccine candidates have been evaluated in preclinical models and are currently in clinical trials. In this Perspective, we discuss three topics that are critical for SARS-CoV-2 vaccine development: antigen selection and engineering, preclinical challenge studies in non-human primate models, and immune correlates of protection.
metadata.artigo.dc.identifier.uri:	https://www.sciencedirect.com/science/article/pii/S1931312820304558 http://repositorio.ufla.br/jspui/handle/1/43154
metadata.artigo.dc.language:	en_US
Appears in Collections:	FCS - Artigos sobre Coronavirus Disease 2019 (COVID-19)

Files in This Item:

There are no files associated with this item.